Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutropin alfa
- Development stage
- Phase 4
- Lead developer
- Merck KGaA
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Lutropin alfa is a recombinant form of human luteinizing hormone (LH), produced using genetically modified Chinese Hamster Ovary (CHO) cells. It is used primarily to treat female infertility due to hypothalamic or pituitary insufficiency, specifically in women with profound LH deficiency who do not have primary ovarian failure. Lutropin alfa mimics the action of endogenous LH by binding to the LH/choriogonadotropic hormone receptor on ovarian theca and granulosa cells, stimulating follicular development and estradiol production when administered with follitropin alfa (FSH). After sufficient follicular maturation, hCG is given to induce ovulation. The drug acts as an agonist at the luteinizing hormone/choriogonadotropin receptor, activating adenylate cyclase and downstream pathways involved in steroidogenesis and follicle maturation[1][4][6]. Lutropin alfa was marketed under the brand name Luveris but has been discontinued in some regions such as the United States[3].
- Brand names
- Luveris
- Other names
- recombinant human luteinizing hormoner-hLH
02
Targets
LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on lutropin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutropin alfa.